Az osteoporosis nem hormonpótló gyógyszeres kezelési lehetöségei.

Translated title of the contribution: Possibilities of non-hormonal drug treatment of osteoporosis

M. Szathmári, R. Châtel

Research output: Contribution to journalArticle

Abstract

In many countries osteoporosis is the most common metabolic bone diseases. A great deal is known about the pathophysiology and the treatment of the disease. There is a lot of treatment possibilities and many new treatments are being tested. Therapeutic agents for osteoporosis are correspondingly classified as substances primarily inhibiting bone turnover (most of them are inhibitors of bone resorption as well) and agents that appear capable of restoring bone mass previously lost (stimulators of bone formation). From a didactic point of view the distinction of these to groups is generally accepted, but pharmacologically there is a considerable overlap between two. In this review the authors evaluate non-hormonal drugs, which are being used widely in the treatment of osteoporosis. The key points of the evaluation are the mechanism of action, the effects on bone mass, bone strength and fracture.

Original languageHungarian
Pages (from-to)2091-2100
Number of pages10
JournalOrvosi Hetilap
Volume140
Issue number38
Publication statusPublished - Sep 19 1999

Fingerprint

Osteoporosis
Pharmaceutical Preparations
Bone Density Conservation Agents
Bone and Bones
Bone Remodeling
Metabolic Bone Diseases
Bone Fractures
Osteogenesis
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Az osteoporosis nem hormonpótló gyógyszeres kezelési lehetöségei. / Szathmári, M.; Châtel, R.

In: Orvosi Hetilap, Vol. 140, No. 38, 19.09.1999, p. 2091-2100.

Research output: Contribution to journalArticle

@article{0d24b5e7db66451995d686e91a3f9371,
title = "Az osteoporosis nem hormonp{\'o}tl{\'o} gy{\'o}gyszeres kezel{\'e}si lehet{\"o}s{\'e}gei.",
abstract = "In many countries osteoporosis is the most common metabolic bone diseases. A great deal is known about the pathophysiology and the treatment of the disease. There is a lot of treatment possibilities and many new treatments are being tested. Therapeutic agents for osteoporosis are correspondingly classified as substances primarily inhibiting bone turnover (most of them are inhibitors of bone resorption as well) and agents that appear capable of restoring bone mass previously lost (stimulators of bone formation). From a didactic point of view the distinction of these to groups is generally accepted, but pharmacologically there is a considerable overlap between two. In this review the authors evaluate non-hormonal drugs, which are being used widely in the treatment of osteoporosis. The key points of the evaluation are the mechanism of action, the effects on bone mass, bone strength and fracture.",
author = "M. Szathm{\'a}ri and R. Ch{\^a}tel",
year = "1999",
month = "9",
day = "19",
language = "Hungarian",
volume = "140",
pages = "2091--2100",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "38",

}

TY - JOUR

T1 - Az osteoporosis nem hormonpótló gyógyszeres kezelési lehetöségei.

AU - Szathmári, M.

AU - Châtel, R.

PY - 1999/9/19

Y1 - 1999/9/19

N2 - In many countries osteoporosis is the most common metabolic bone diseases. A great deal is known about the pathophysiology and the treatment of the disease. There is a lot of treatment possibilities and many new treatments are being tested. Therapeutic agents for osteoporosis are correspondingly classified as substances primarily inhibiting bone turnover (most of them are inhibitors of bone resorption as well) and agents that appear capable of restoring bone mass previously lost (stimulators of bone formation). From a didactic point of view the distinction of these to groups is generally accepted, but pharmacologically there is a considerable overlap between two. In this review the authors evaluate non-hormonal drugs, which are being used widely in the treatment of osteoporosis. The key points of the evaluation are the mechanism of action, the effects on bone mass, bone strength and fracture.

AB - In many countries osteoporosis is the most common metabolic bone diseases. A great deal is known about the pathophysiology and the treatment of the disease. There is a lot of treatment possibilities and many new treatments are being tested. Therapeutic agents for osteoporosis are correspondingly classified as substances primarily inhibiting bone turnover (most of them are inhibitors of bone resorption as well) and agents that appear capable of restoring bone mass previously lost (stimulators of bone formation). From a didactic point of view the distinction of these to groups is generally accepted, but pharmacologically there is a considerable overlap between two. In this review the authors evaluate non-hormonal drugs, which are being used widely in the treatment of osteoporosis. The key points of the evaluation are the mechanism of action, the effects on bone mass, bone strength and fracture.

UR - http://www.scopus.com/inward/record.url?scp=0033584563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033584563&partnerID=8YFLogxK

M3 - Article

C2 - 10531790

AN - SCOPUS:0033584563

VL - 140

SP - 2091

EP - 2100

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 38

ER -